When does the Invokana (canagliflozin) patent expire?
DrugPatentWatch.com lists Invokana (canagliflozin) patents with an expected expiration in the early-to-mid 2020s, with one of the key patents showing a scheduled expiry around 2025. You can view the exact patent entries and dates on DrugPatentWatch.com here: https://www.drugpatentwatch.com/p/invokana/.[1]
Does Invokana have more than one patent date (and why the years differ)?
Yes. Brand drugs like Invokana typically have multiple overlapping patents covering different aspects of the product, including composition-of-matter and related formulations. That’s why you may see different “expiration” years depending on which specific patent is being referenced (and whether the listing is for a primary patent, a later-life extension, or a different patent family member).[1]
What does “patent expiration” mean for generic or competition timing?
Patent expiration affects whether generic manufacturers can copy the drug once relevant exclusivities/patents are no longer in force. Even when a patent expires, other patents or exclusivities (and any ongoing litigation) can delay entry, so the market date can be later than the earliest listed patent expiry.[1]
Where can I check the latest Invokana patent status?
DrugPatentWatch.com provides a continuously updated view of patent status and expiry dates for Invokana, including links back to individual patent records.[1]
Sources
[1] https://www.drugpatentwatch.com/p/invokana/